Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 4/1998

Content (13 Articles)

ORIGINAL ARTICLE

Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection

Sherman F. Stinson, Kimberly Hill, Timothy J. Siford, Lawrence R. Phillips, Tracy W. Daw

ORIGINAL ARTICLE

Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

Kiyoshi Takasuna, Takehiro Hagiwara, Masaaki Hirohashi, Michiyuki Kato, Mamoru Nomura, Eiichi Nagai, Tsuyoshi Yokoi, Tetsuya Kamataki

ORIGINAL ARTICLE

Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine

Joseph F. Foss, Chun-Su Yuan, Michael F. Roizen, Leon I. Goldberg

ORIGINAL ARTICLE

Fluorescence methods to assess multidrug resistance in individual cells

Eric J. Nelson, Noah T. Zinkin, Patricia M. Hinkle

ORIGINAL ARTICLE

Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice

Joel E. Wright, Mario Pardo, Anatoly Tretyakov, Wendy L. Alperin, Dorothy Trites, Andre Rosowsky

ORIGINAL ARTICLE

Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo

Joseph Paul Eder, Victor Chan, Julia Wong, Yee W. Wong, Gulshan Ara, David Northey, Naiyer Rizvi, Beverly A. Teicher

CLINICAL TRIAL REPORT

Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy

Silvana Chiara, Maria Teresa Nobile, Maura Vincenti, Rita Lionetto, Alberto Gozza, Maria Cristina Barzacchi, Ornella Sanguineti, Lazzaro Repetto, Riccardo Rosso

SHORT COMMUNICATION

Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study

Kiyotaka Okuno, Norihiko Hirai, Yung Sun Lee, Dino Tarabar, Hideo Ueno, Masayuki Yasutomi

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine